Adult Dosing

Mild to moderate atopic dermatitis [Desonate, Verdeso]

• Apply to affected area(s) as a thin film bid, (Max: 4 wks)

Corticosteroid-responsive dermatoses [Desowen, LoKara, desonide (generic)]

• Apply to affected area(s) as a thin film bid-tid, (Max: 2 wks)

• Do not use occlusive dressing

Pediatric Dosing

Mild to moderate atopic dermatitis [Desonate, Verdeso]

• >3 months: Apply to affected area(s) as a thin film bid, (Max: 4 wks)

Corticosteroid-responsive dermatoses [Desowen, LoKara, desonide (generic)]

• Pediatric dosing not available

Note:

• Do not use occlusive dressing

[Outline]

• Adult Dosing
• Pediatric Dosing

• Mild to moderate atopic dermatitis [Desonate, Verdeso]
• Inflammatory and pruritic corticosteroid-responsive dermatoses [Desowen, LoKara, desonide (generic) ]

• Hypersensitivity to any of the ingredients of the product

• N/A

Renal Dose Adjustment

• Renal impairment: No dose adjustments

Hepatic Dose Adjustment

• Hepatic impairment: No dose adjustments

See Supplemental Patient Information

• Reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia and glucosuria occurs due to systemic absorption of topical corticosteroid, application of the more potent steroids over large surface areas, prolonged use and occlusive dressing add on to the systemic absorption. Monitor the patient periodically for HPA axis suppression, discontinue or reduce the frequency of application, or substitute with a less potent steroid if HPA- axis suppression noted
• Pediatric patients are more susceptible to systemic toxicity (HPA axis suppression, Cushing's syndrome and intracranial hypertension) as proportionally larger amounts of topical corticosteroids is absorbed. Limit the use to the least amount compatible with an effective therapeutic regimen
• If irritation develops, discontinue the drug and start appropriate therapy
• If dermatological infection occurs provide appropriate antifungal or antibacterial therapy, temporarily discontinue topical corticosteroid until the infection has been adequately controlled

Cautions: Use cautiously in

• Skin infection
• Pediatric patients

Supplemental Patient Information

• Patients should be advised not to bandage or otherwise cover or wrap the affected area(s) unless directed by their physician

Pregnancy Category:C

Breastfeeding: No studies conducted during breastfeeding; short-term application of topical corticosteroids is not expected to pose a risk to the breastfed infant by passage into breastmilk. Use of the least potent drug on the smallest area of skin of mother is recommended. Ensure that the infant's skin does not come into direct contact with the areas treated with this drug. Use of lower potency corticosteroids, water-miscible cream products on the nipple or areola is recommended. Any topical corticosteroid should be wiped off thoroughly prior to nursing if it is applied to the nipple or areola. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 29 December 2010) However manufacturer advises caution while administrating nursing mothers.

• DERM: Burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneform eruption, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration, secondary infection, skin atrophy, striae, miliaria
• RESP: URTI, cough, asthma, pharyngitis
• CNS: Headache
• META: Hyperglycemia
• CNS: Interacranial hypertension
• MISC: Adrenal suppression, cushing syndrome

• Corticosteroid; exact mechanism of action unknown; induce phospholipase A2 inhibitory proteins (lipocortins). These proteins inhibits release of their common precursor arachidonic acid thereby controlling the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes
• Minimal systemic availability after topical application. Presence of inflammation and occlusive dressings increase systemic absorption
• Metabolized primarily by liver; CYP450: Unknown
• Renally excreted; minimally in bile
• Half-life: Unknown

US Trade Name(s)

• Desonate
• Desowen
• LoKara
• Verdeso

US Availability

desonide (generic)

• CRE: 0.05% (15, 60 g)
• OINT: 0.05% (15, 60 g)
• LOTN: 0.05% (59, 118 mL)

Desonate

• GEL: 0.05% (60 g)

Desowen

• CRE: 0.05% (60 g)
• LOTN: 0.05% (59, 118 mL)
• OINT: 0.05% (60 g)

LoKara

• LOTN: 0.05% (59 mL bottle)

Verdeso

• Aerosol Foam: 0.05% (50, 100 g)

Canadian Trade Name(s)

• Desocort
• Tridesilon

Canadian Availability

Desonide (generic)

• CRE: 0.05%
• OINT: 0.05%

Desocort

• OINT : 0.05%
• LOTN: 0.05%

Tridesilon

• CRE: 0.05%
• OINT: 0.05%

UK Trade Name(s)

• N/A

UK Availability

Australian Trade Name(s)

• Desowen

Australian Availability

Desowen

• LOTN: 0.05% (60 mL)

[Outline]

Dermatologic

Dermatologic Topical Agents

Steroids

Pricing data from www.DrugStore.com in U.S.A.

• Desonide 0.05 % CREA [Tube] (PERRIGO PHARMACEUTICALS)
  60 % = $39.99
  120 % = $75.97
• Desonate 0.05 % GEL [Tube] (INTENDIS)
  60 % = $405.98
  180 % = $1176.02
• Desonide 0.05 % LOTN [Bottle] (FOUGERA)
  118 % = $210
  354 % = $575.96
• Verdeso 0.05 % FOAM [Can] (GLAXO SMITH KLINE)
  100 % = $328.97
  300 % = $906.99
• Verdeso 0.05 % FOAM [Can] (GLAXO SMITH KLINE)
  50 % = $178.98
  150 % = $511.99
• Desonide 0.05 % CREA [Tube] (PERRIGO PHARMACEUTICALS)
  15 % = $23.99
  45 % = $50.97
• DesOwen 0.05 % LOTN [Bottle] (GALDERMA)
  118 % = $190.08
  354 % = $554
• Desonide 0.05 % OINT [Tube] (PERRIGO PHARMACEUTICALS)
  60 % = $33.99
  180 % = $89.96
• Desonide 0.05 % LOTN [Bottle] (FOUGERA)
  59 % = $145.99
  177 % = $415.96
• Desonide 0.05 % OINT [Tube] (PERRIGO PHARMACEUTICALS)
  15 % = $21.99
  45 % = $45.97

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.